• 1
    Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006;103: 593540.
  • 2
    Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006;442:44852.
  • 3
    Halloran ME, Ferguson NM, Eubank S, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci USA 2008;105:463944.
  • 4
    US Department of Health and Human Services. HHS pandemic influenza plan [monograph on the Internet]. Washington; 2005. Available from:[Accessed July 2, 2007].
  • 5
    Committee on Modeling Community Containment for Pandemic Influenza. Modeling community containing pandemic influenza: a letter report 2006 [monograph on the Internet]. Washington, The National Academies Press; 2006. Available from:[Accessed July 2, 2007].
  • 6
    Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18:326382.
  • 7
    Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:62333.
  • 8
    Halloran ME, Longini IM, Cowart DM, Nizam A. Community interventions and the epidemic prevention potential. Vaccine 2002;20:325462.
  • 9
    Elveback LR, Fox JP, Ackerman E, et al. An influenza simulation model for immunization studies. Am J Epidemiol 1976;103:15265.
  • 10
    Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:128493.
  • 11
    Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007;165:21221.
  • 12
    Longini IM, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005;309: 10837.
  • 13
    Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol 1990;28:36582.
  • 14
    Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000;343:12829.
  • 15
    Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:74854.
  • 16
    Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:133643.
  • 17
    Yang Y, Longini IM, Halloran ME. Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. Appl Stat 2006;55:31730.
  • 18
    Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:166772.
  • 19
    Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:83442.
  • 20
    Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004;432:9046.
  • 21
    Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7:1170.
  • 22
    Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig 2006;26:32940.
  • 23
    Sander B, Gyldmark M, Aultman R, Aoki FY. Impact on health outcomes and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 2004;7:6783.
  • 24
    Denis M. Pandemic vaccines: development status [abstract]. Presented at: Pandemic Influenza Vaccines. Building a Platform for Global Collaboration, January 28–30, 2007, Beijing, China.
  • 25
    Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 2005;3:17.
  • 26
    Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004; 113:28390.
  • 27
    Gold MR, Siegel JR, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 28
    Nettleman MD, White T, Lavoie S, Chafin C. School absenteeism, parental work loss, and acceptance of childhood influenza vaccination. Am J Med Sci 2001;321:17880.
  • 29
    Rothberg MB, Fisher D, Kelly B, Rose DN. Management of influenza symptoms in healthy children: cost effectiveness of rapid testing and antiviral therapy. Arch Pediatr Adolesc Med 2005;159:105562.
  • 30
    US Department of Education Institute of Education Sciences; National Center for Educations Statistics. Digest of education statistics 2005. Available from:[Accessed November 7, 2006].
  • 31
    Physicians Desk Reference. Red Book: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale: PDR Thomson, 2006.
  • 32
    OANDA. FxConverter—Currency Converter for 164 Currencies. The Currency Site. 2006. Available from:[Accessed July 5, 2006].
  • 33
    Schulpher M. The role and estimation of productivity costs in economic evaluation. In: DrummondM, ed., Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford University Press, 2001.
  • 34
    US Department of Labor: Bureau of Labor Statistics. Compensation cost trends 2006. Available from:[Accessed November 7, 2006].
  • 35
    US Department of Education Institute of Education Sciences; National Center for Educations Statistics. Projections of education statistics to 2015. Available from:[Accessed November 7, 2006].
  • 36
    Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:162730.
  • 37
    Congressional Budget Office. A potential influenza pandemic: an update on possible macroeconomic effects and policy issues. 2006. Available from:[Accessed November 7, 2006].